Transplant Considerations

Results of a recent study suggest that delaying autologous stem-cell transplantation (ASCT) after immunomodulatory therapy is effective and leads to comparable survival rates as with early transplantation in patients with multiple myeloma (Kumar SK, et al. Cancer. 2012;118:1585-1592). The study results indicate that survival outcomes are not compromised when ASCT is delayed if stem cells are harvested early; however, the study was not randomized and was conducted before the bortezomib era.

Value-Based Care in MyelomaTM (VBM) asked transplant specialist
Sergio A. Giralt, MD, Chief of the Adult Bone Marrow Transplant Service at Memorial Sloan-Kettering Cancer Center, New York, to discuss his transplant strategy for patients with multiple myeloma, and where the field is heading.

Results 1 - 6 of 6
  • American Health & Drug Benefits
  • Lynx CME
  • Value-Based Care in Myeloma
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology